Product class: Authorized package
Medicinal product class: For human use
Package code: 1809187
Name of medicinal product: BAQSIMI
Active substances:
Estonian, English, Latin
ATC code: H04AA01
Dosage form: nasal powder in single-dose container
Route of administration: nasal use
Strengh: 3mg
Amount in package: 2TK
Legal status for supply*: Subject to medicinal prescription
Class of active substance:  
Additional information:  
Indication: Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.
Safety features: Yes
Summary of product characteristics (SPC):
Package information leaflet (PIL): EST
Last imported to Estonia: Never imported to Estonia
Marketing authorization holder: Eli Lilly Nederland B.V. 
Marketing authorization number: EU/1/19/1406 
Marketing authorization issued on: 16 December 2019 
Marketing authorization expires on: 18 December 2024 
Marketing authorization procedure type: Centralised 
Reference price:   
Under reference price:   
Reference price of daily dose:   
Entry/Changing date: 08 January 2020
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription